Lauren Harvey

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

Yelena Kovtun, Gregory E. Jones, Sharlene Adams et al. · Blood Advances · 2018 · 176 citations · Full text

Pharmacy, Molecular Pharmaceutics, Oncology +15

IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML

Yelena Kovtun, Paul Noordhuis, Kathleen R. Whiteman et al. · Molecular Cancer Therapeutics · 2018 · 77 citations · Full text

Medicine, Oncology, Pharmacology +13

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)

Michael L. Miller, Manami Shizuka, Alan Wilhelm et al. · Molecular Cancer Therapeutics · 2018 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Kathleen R. Whiteman, Paul Noordhuis, R. Walker et al. · Blood · 2014 · 35 citations

Pharmacy, Medicinal Chemistry, Oncology +17

Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation

Chen Bai, Emily E. Reid, Alan Wilhelm et al. · Bioconjugate Chemistry · 2019 · 34 citations · Full text

Pharmacy, Oncology, Pharmacology +17